Free Newsletter
GSK gets Boostrix approval for adults over 65
GlaxoSmithKline has gained FDA approval for its tetanus, diphtheria and whooping cough vaccine Boostrix in adults 65 and older. It's the first vaccine that protects older adults from all three diseases with a single shot. With the expanded indication, the vaccine can now be given to people over the age of 10.
"Although many people may have been vaccinated against whooping cough as children, immunity can wear off over time," explained GSK VP of Medical Affairs Leonard Friedland. "Adults, including those age 65 and older, should speak with their healthcare providers to make sure their vaccinations are up to date and to discuss the Centers for Disease Control and Prevention's recommendations for preventing tetanus, diphtheria and pertussis."
Whooping cough cases are on the rise due in part to some parents refusing to get their children vaccinated. Michigan, Ohio, New York and Pennsylvania have all reported a rise in cases of the disease, and California declared a whooping cough epidemic in 2010.
- here's GSK's release
- read more from UPI
Related Articles:
Expanded indication for GSK's Boostrix approved
Vaccination gaps contribute to pertussis outbreak
Comments
Post a comment
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: